Pangenotypic Glecaprevir/Pibrentasvir Therapy for Chronic Hepatitis C in Children
Eight-week GLE/PIB therapy in children is well tolerated and highly effective in all age ranges regardless of gender. Its use in routine clinical practice will bring the ambitious goal of eliminating HCV worldwide a step closer.
Authors
- Krystyna Dobrowolska (ORCID: https://orcid.org/0000-0003-0352-9893)
- Justyna Moppert
- Robert Flisiak (ORCID: https://orcid.org/0000-0003-3394-1635)
- Maria Pokorska‐Śpiewak (ORCID: https://orcid.org/0000-0001-7783-6904)
- Ewa Majda-Stanisławska (ORCID: https://orcid.org/0000-0002-7178-5293)
- Anna Mania (ORCID: https://orcid.org/0000-0003-0141-2560)
- Małgorzata Pawłowska (ORCID: https://orcid.org/0000-0002-6044-0425)
- Dorota Zarębska‐Michaluk (ORCID: https://orcid.org/0000-0003-0938-1084)
- Zuzanna Kalinowska
Institutions
- Poznan University of Medical Sciences (PL)
- Medical University of Białystok (PL)
- Jan Kochanowski University (PL)
- Medical University of Warsaw (PL)
- Nicolaus Copernicus University (PL)
- Uniwersytecki Szpital Dziecięcy (PL)
- Medical University of Lodz (PL)
Publication Details
- Journal
- The Pediatric Infectious Disease Journal
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1097/inf.0000000000005069
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00